Figure 1.

CSF IGFBP2 levels progressively increase over 5 years in asymptomatic PREVENT-AD participants. IGFBP2 was measured in the CSF of a subset of PREVENT-AD participants (n = 27) at baseline and at follow-up visits, using the Olink Proximity Extension Assay. Linear mixed models accounting for participant-specific trajectories demonstrate CSF IGFBP2 levels increase in a subset of at-risk individuals that have been followed for 5 years. β- and P-values are located in the top left corner. IGFBP2 = insulin-like growth factor binding protein-2; PREVENT-AD = PRe-symptomatic EValuation of Experimental or Novel Treatments for Alzheimer's Disease; NPX = Normalized Protein eXpression.